Basic Information
Rigvir Group is a private organization composed of multiple companies that has been developing oncolytic virus therapies since 2002. At the core of the organization's strategy are the production of the unique oncolytic ECHO-7 virus, maintaining an efficient R&D team, precision manufacturing, drug development, and marketing. We are committed to providing virotherapy worldwide to save and improve the lives of cancer patients today and in the future. Rigvir Group was the world’s first company to register an oncolytic virus and systematically train qualified healthcare professionals for its clinical use, making us the most experienced organization in the development and clinical practice of oncolytic viruses.